Drug & intervention

mitoxantrone

RxCUI 7005

Clinical trials17
Recruiting0
Related conditions15
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Mitoxantrone

Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent.

Read on Wikipedia ↗ Wikidata Q239426 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

17 shown
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate CancerNCT01594918 · 2012-06-01
COMPLETED
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443 · 2012-03-01
TERMINATED
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple SclerosisNCT02937285 · 2010-12-06
COMPLETED
A Study of Olaratumab (IMC-3G3) in Prostate CancerNCT01204710 · 2010-10-01
COMPLETED
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate CancerNCT00770848 · 2008-11-01
COMPLETED
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate CancerNCT00683475 · 2008-08-01
COMPLETED
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)NCT00661492 · 2008-05-01
COMPLETED
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)NCT00452387 · 2007-05-01
TERMINATED
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate CancerNCT00417079 · 2007-01-01
COMPLETED
Taxotere Prostate Cancer New Indication Registration Trial in ChinaNCT00436839 · 2007-01-01
COMPLETED
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)NCT00385827 · 2006-11-01
TERMINATED
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate CancerNCT00447473 · 2006-07-01
TERMINATED
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate CancerNCT00477087 · 2006-07-01
TERMINATED
Study Evaluating Mitoxantrone in Multiple SclerosisNCT00146159 · 2005-03-01
TERMINATED
Study of Irofulven in Patients With Hormone-refractory Prostate CancerNCT00124566 · 2004-06-01
COMPLETED
S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone TherapyNCT00004001 · 1999-10-01
COMPLETED
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple SclerosisNCT00219908 · 1999-07-01
TERMINATED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.